These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35720322)

  • 1. Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals.
    Munroe ME; Young KA; Guthridge JM; Kamen DL; Gilkeson GS; Weisman MH; Ishimori ML; Wallace DJ; Karp DR; Harley JB; Norris JM; James JA
    Front Immunol; 2022; 13():866181. PubMed ID: 35720322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.
    Munroe ME; Young KA; Kamen DL; Guthridge JM; Niewold TB; Costenbader KH; Weisman MH; Ishimori ML; Wallace DJ; Gilkeson GS; Karp DR; Harley JB; Norris JM; James JA
    Arthritis Rheumatol; 2017 Mar; 69(3):630-642. PubMed ID: 27863174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.
    Lu R; Munroe ME; Guthridge JM; Bean KM; Fife DA; Chen H; Slight-Webb SR; Keith MP; Harley JB; James JA
    J Autoimmun; 2016 Nov; 74():182-193. PubMed ID: 27338520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
    Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
    Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathways of impending disease flare in African-American systemic lupus erythematosus patients.
    Munroe ME; Vista ES; Merrill JT; Guthridge JM; Roberts VC; James JA
    J Autoimmun; 2017 Mar; 78():70-78. PubMed ID: 28162788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
    Aberle T; Bourn RL; Munroe ME; Chen H; Roberts VC; Guthridge JM; Bean K; Robertson JM; Sivils KL; Rasmussen A; Liles M; Merrill JT; Harley JB; Olsen NJ; Karp DR; James JA
    Arthritis Care Res (Hoboken); 2017 Dec; 69(12):1780-1788. PubMed ID: 28118528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-degree relatives of patients with systemic lupus erythematosus: Autoreactivity but not autoimmunity?
    Penev B; Vasilev G; Todorova EI; Tumangelova-Yuzeir K; Kurteva E; Monov S; Kyurkchiev D
    Int J Rheum Dis; 2023 May; 26(5):907-916. PubMed ID: 36942901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
    Slight-Webb S; Lu R; Ritterhouse LL; Munroe ME; Maecker HT; Fathman CG; Utz PJ; Merrill JT; Guthridge JM; James JA
    Arthritis Rheumatol; 2016 Oct; 68(10):2492-502. PubMed ID: 27059145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls.
    Young KA; Terrell DR; Guthridge JM; Kamen DL; Gilkeson GS; Karp DR; Ishimori ML; Weisman MH; Holers VM; Harley JB; Norris JM; James JA
    Lupus; 2014 Apr; 23(4):360-9. PubMed ID: 24449338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.
    Munroe ME; Vista ES; Guthridge JM; Thompson LF; Merrill JT; James JA
    Arthritis Rheumatol; 2014 Jul; 66(7):1888-99. PubMed ID: 24578190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus.
    Munroe ME; Blankenship D; DeFreese D; Purushothaman M; DeJager W; Macwana S; Guthridge JM; Kamp S; Redinger N; Aberle T; Chakravarty EF; Arriens C; Li Y; Zeng H; McCarthy-Fruin KA; Osei-Onomahm SA; Thanarajasingam U; James JA; Jupe E
    Arthritis Rheumatol; 2023 May; 75(5):723-735. PubMed ID: 36245261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients.
    James JA; Chen H; Young KA; Bemis EA; Seifert J; Bourn RL; Deane KD; Demoruelle MK; Feser M; O'Dell JR; Weisman MH; Keating RM; Gaffney PM; Kelly JA; Langefeld CD; Harley JB; Robinson W; Hafler DA; O'Connor KC; Buckner J; Guthridge JM; Norris JM; Holers VM
    EBioMedicine; 2019 Apr; 42():76-85. PubMed ID: 30952617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus.
    Aberle T; Bourn RL; Chen H; Roberts VC; Guthridge JM; Bean K; Robertson JM; Sivils KL; Rasmussen A; Liles M; Merrill JT; Harley JB; Olsen NJ; Karp DR; James JA
    Lupus Sci Med; 2017; 4(1):e000176. PubMed ID: 28409015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort.
    Lambers W; Arends S; Roozendaal C; Brouwer E; Bootsma H; Westra J; de Leeuw K
    Lupus Sci Med; 2021 Nov; 8(1):. PubMed ID: 34795031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus.
    Antiga E; Del Bianco E; Difonzo E; Fabbri P; Caproni M
    Lupus; 2011 May; 20(6):556-60. PubMed ID: 21372199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin.
    Lambers WM; de Leeuw K; Doornbos-van der Meer B; Diercks GFH; Bootsma H; Westra J
    Arthritis Res Ther; 2019 Dec; 21(1):260. PubMed ID: 31791398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE.
    Young KA; Munroe ME; Guthridge JM; Kamen DL; Gilkensen GS; Harley JB; Weisman MH; Karp DR; Wallace DJ; James JA; Norris JM
    Lupus; 2019 Apr; 28(5):597-606. PubMed ID: 30845880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between a Vitamin D Genetic Risk Score and Autoantibodies Among First-Degree Relatives of Probands With Rheumatoid Arthritis and Systemic Lupus Erythematosus.
    Vanderlinden LA; Bemis EA; Seifert J; Guthridge JM; Young KA; Demoruelle MK; Feser M; DeJager W; Macwana S; Mikuls TR; O'Dell JR; Weisman MH; Buckner J; Keating RM; Gaffney PM; Kelly JA; Langefeld CD; Deane KD; James JA; Holers VM; Norris JM
    Front Immunol; 2022; 13():881332. PubMed ID: 35720397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.
    Li QZ; Zhou J; Wandstrat AE; Carr-Johnson F; Branch V; Karp DR; Mohan C; Wakeland EK; Olsen NJ
    Clin Exp Immunol; 2007 Jan; 147(1):60-70. PubMed ID: 17177964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.